Literature DB >> 24241488

Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.

Fabio Efficace1, Gianantonio Rosti, Neil Aaronson, Francesco Cottone, Emanuele Angelucci, Stefano Molica, Marco Vignetti, Franco Mandelli, Michele Baccarani.   

Abstract

The main objective of this study was to compare the reporting of health status and symptom severity, for a set of core symptoms related to imatinib therapy, between chronic myeloid leukemia patients and their treating physicians. Patients were asked to complete a questionnaire including questions on symptom severity and health status. The symptoms assessed were: abdominal discomfort, diarrhea, edema, fatigue, headache, muscle cramps, musculoskeletal pain, nausea and skin problems. The physicians were asked to complete a questionnaire for each of their patients entering the study. Four hundred twenty-two patients were included in the study. All respective paired physicians (n=29) completed the questionnaire, and thus the analyses are based on 422 patient-physician dyads. Agreement on symptom ratings ranged from 34% (for muscle cramps) to 66% (for nausea). For all symptoms, patients reported higher severity more often than their physicians. The three symptoms whose severity was most frequently underestimated by physicians were fatigue (51%), muscle cramps (49%) and musculoskeletal pain (42%). Health status was overestimated by physicians in 67% of the cases. Physicians and their patients with chronic myeloid leukemia often disagree in their ratings of the patients' symptom severity. Most typically, physicians tend to underestimate symptom severity and overestimate the overall health status of their patients. Current findings support the use of patient-reported outcome measures as a possible means to enhance the management of patients with chronic myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24241488      PMCID: PMC3971090          DOI: 10.3324/haematol.2013.093724

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  28 in total

1.  International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

Authors:  Fabio Efficace; Michele Baccarani; Massimo Breccia; Susanne Saussele; Gregory Abel; Giovanni Caocci; Francois Guilhot; Kim Cocks; Adel Naeem; Mirjam Sprangers; Simone Oerlemans; Weichu Chie; Fausto Castagnetti; Felice Bombaci; Giora Sharf; Annarita Cardoni; Lucien Noens; Stephan Pallua; Marzia Salvucci; Ourania Nicolatou-Galitis; Gianantonio Rosti; Franco Mandelli
Journal:  Qual Life Res       Date:  2013-09-13       Impact factor: 4.147

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Lack of congruence in the ratings of patients' health status by patients and their physicians.

Authors:  M E Suarez-Almazor; B Conner-Spady; C J Kendall; A S Russell; K Skeith
Journal:  Med Decis Making       Date:  2001 Mar-Apr       Impact factor: 2.583

4.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

5.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.

Authors:  Ethan Basch; Alexia Iasonos; Tiffani McDonough; Allison Barz; Ann Culkin; Mark G Kris; Howard I Scher; Deborah Schrag
Journal:  Lancet Oncol       Date:  2006-11       Impact factor: 41.316

6.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

Authors:  Erik K Fromme; Kristine M Eilers; Motomi Mori; Yi-Ching Hsieh; Tomasz M Beer
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

7.  Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study.

Authors:  Doranne L Hilarius; Paul H Kloeg; Chad M Gundy; Neil K Aaronson
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

8.  Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

Authors:  Lucien Noens; Marie-Anne van Lierde; Robrecht De Bock; Gregor Verhoef; Pierre Zachée; Zwi Berneman; Philippe Martiat; Philippe Mineur; Koen Van Eygen; Karen MacDonald; Sabina De Geest; Tara Albrecht; Ivo Abraham
Journal:  Blood       Date:  2009-04-06       Impact factor: 22.113

9.  Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial.

Authors:  Galina Velikova; Laura Booth; Adam B Smith; Paul M Brown; Pamela Lynch; Julia M Brown; Peter J Selby
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

10.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

View more
  25 in total

Review 1.  The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.

Authors:  Hemant S Murthy; William A Wood
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 2.  Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden.

Authors:  Michele Baccarani; Fabio Efficace; Gianantonio Rosti
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

3.  Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing.

Authors:  Markus K Schuler; Freya Trautmann; Mirko Radloff; Roman Schmädig; Leopold Hentschel; Maria Eberlein-Gonska; Thomas Petzold; Heike Vetter; Sebastian Oberlack; Gerhard Ehninger; Jochen Schmitt
Journal:  Support Care Cancer       Date:  2016-03-16       Impact factor: 3.603

4.  Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.

Authors:  Jorge E Cortes; Carlo Gambacorti-Passerini; Michael W Deininger; Michael J Mauro; Charles Chuah; Dong-Wook Kim; Dragana Milojkovic; Philipp le Coutre; Valentin Garcia-Gutierrez; Rocco Crescenzo; Carla Mamolo; Arlene Reisman; Andreas Hochhaus; Tim H Brümmendorf
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-15       Impact factor: 4.553

5.  Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine.

Authors:  G Graffigna; I Cecchini; M Breccia; E Capochiani; R Della Seta; S Galimberti; A Melosi; F Simonetti; M Pizzuti; S F Capalbo; F Falzetti; P Mazza; N Di Renzo; L Mastrullo; D Rapezzi; E Orlandi; T Intermesoli; A Iurlo; E Pungolino; M Pacilli
Journal:  Qual Life Res       Date:  2017-06-12       Impact factor: 4.147

6.  Increased Incidence of Fatigue in Patients with Primary Immunodeficiency Disorders: Prevalence and Associations Within the US Immunodeficiency Network Registry.

Authors:  Joud Hajjar; Danielle Guffey; Charles G Minard; Jordan S Orange
Journal:  J Clin Immunol       Date:  2017-01-26       Impact factor: 8.317

7.  Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.

Authors:  Momar Diouf; Franck Bonnetain; Jean-Claude Barbare; Olivier Bouché; Laetitia Dahan; Xavier Paoletti; Thomas Filleron
Journal:  Oncologist       Date:  2014-12-26

Review 8.  The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.

Authors:  Thomas M Atkinson; Sean J Ryan; Antonia V Bennett; Angela M Stover; Rebecca M Saracino; Lauren J Rogak; Sarah T Jewell; Konstantina Matsoukas; Yuelin Li; Ethan Basch
Journal:  Support Care Cancer       Date:  2016-06-03       Impact factor: 3.603

9.  Electronic real-time assessment of patient-reported outcomes in routine care-first findings and experiences from the implementation in a comprehensive cancer center.

Authors:  Freya Trautmann; Leopold Hentschel; Beate Hornemann; Anke Rentsch; Michael Baumann; Gerhard Ehninger; Jochen Schmitt; Markus Schuler
Journal:  Support Care Cancer       Date:  2016-02-18       Impact factor: 3.603

10.  Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer.

Authors:  Ashlyn Tom; Antonia V Bennett; Diana Rothenstein; Ethel Law; Karyn A Goodman
Journal:  Qual Life Res       Date:  2017-09-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.